Contineum Therapeutics
10578 Science Center Drive
Suite 200
San Diego
California
92121
United States
Tel: 8583497880
Website: https://www.contineum-tx.com/
Email: info@pipeline-tx.com
45 articles about Contineum Therapeutics
-
Pipeline Therapeutics to Present at Multiple Investor Conferences in May 2022
5/11/2022
Pipeline Therapeutics announced that company management will present at the following investor conferences.
-
Pipeline Therapeutics to Present at the 21st Annual Virtual Needham Healthcare Conference
4/5/2022
Pipeline Therapeutics to Present at the 21st Annual Virtual Needham Healthcare Conference.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Four companies, Pipeline Therapeutics, Prothena, Neuroplast, and Taysha Gene Therapies, announced launches of clinical trials in the CNS space.
-
Pipeline Therapeutics Receives IND Clearance from FDA to Initiate Phase 1b/2a Study of PIPE-307 in Patients with Relapsing-Remitting Multiple Sclerosis
3/28/2022
Pipeline Therapeutics today announced that the U.S. Food and Drug Administration (FDA) cleared the company to initiate its Phase 1b/2a clinical trial of PIPE-307 in patients with relapsing-remitting multiple sclerosis (RRMS).
-
Pipeline Therapeutics to Present at Upcoming March Investor Conferences
3/14/2022
Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair.
-
Across a range of indications, COVID-19-related and non-COVID-19-related, there was plenty of clinical trial news last week.
-
Pipeline Therapeutics Reports Positive Phase 1 Clinical Results for PIPE-307, a Neuroregenerative Therapeutic for the Treatment of Multiple Sclerosis
3/10/2022
Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, today reported positive clinical data from its recently completed Phase 1 clinical trial evaluating the safety and tolerability of PIPE-307 in healthy volunteers.
-
Pipeline Therapeutics Appoints Eef Schimmelpennink to its Board of Directors
2/15/2022
Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, announced the appointment of Evert Schimmelpennink to its Board of Directors.
-
Pipeline Therapeutics to Participate in the Stifel 2021 Virtual Healthcare and Jefferies London Healthcare Conferences
11/10/2021
Pipeline Therapeutics today announced that the company will participate in two upcoming investor conferences.
-
Pipeline Therapeutics Appoints Scott Oross as General Counsel
6/25/2021
Pipeline Therapeutics today announced that Scott Oross has been appointed as General Counsel.
-
Pipeline Therapeutics Initiates Phase 1 Clinical Trial of PIPE-307
3/2/2021
Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the initiation of a Phase 1 study of PIPE-307, a selective antagonist of the muscarinic M1 receptor, in up to 72 healthy volunteers.
-
Pipeline Therapeutics Completes $80 Million Series C Financing
2/11/2021
Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the closing of an $80 million Series C financing.
-
Pipeline Therapeutics to Participate in the 2020 RBC Capital Markets and SVB Leerink Private Company Conferences
12/8/2020
Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the company will participate in two upcoming investor conferences in December. 2020 RBC Capital Markets Healthcare Private Company Conference Format: Analyst-Led Fireside Chat Date: Tuesday, December 15, 2020 Time: 9:20 a.m. ET / 6:20 a.m. PT
-
Pipeline Therapeutics Appoints Julie Iwashita as Vice President of Clinical Operations
12/3/2020
Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Julie Iwashita as the company’s Vice President of Clinical Operations. Ms. Iwashita brings more than 30 years of experience guiding global neurology and other clinical development programs through the U.S. Food and Drug Administration (FDA
-
Pipeline Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
11/16/2020
Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that Carmine Stengone, President and Chief Executive Officer, will participate in a fireside chat and investor meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference, a fully virtual management access conference, taking place December 1-3.
-
Pipeline Therapeutics to Present at Stifel 2020 Virtual Healthcare Conference
11/12/2020
Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that Carmine Stengone, President and Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, at 2:00 p.m. ET / 11:00 a.m. PT. About Pipeline Therapeutics Pipeline Therapeutics is a biopha
-
Pipeline Therapeutics Appoints Peter Slover as Chief Financial Officer
10/15/2020
Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Peter Slover as the company’s Chief Financial Officer.
-
Pipeline Therapeutics to Present at BMO’s Fall Private Company Showcase 2020
10/8/2020
Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that Carmine Stengone, President and Chief Executive Officer, will present at the Fall Private Company Showcase 2020, co-hosted by BMO, a fully virtual management access conference, on Thursday, October 15, at 1:40 p.m. ET / 10:40 a.m. PT.
-
Pipeline Therapeutics Appoints Lori Lyons-Williams to its Board of Directors
9/18/2020
Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Lori Lyons-Williams to the company’s Board of Directors. Ms. Lyons-Williams brings more than 20 years of executive and operational experience to Pipeline. “I am thrilled that Lori will be joining the Pipeline board as an indepe